AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20718545 — intervention group
Group type: COMPARATOR
Intervention: Daily positive thoughts about the partner or a neutral activity
Number of subjects: 375
Study 17701114 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional advice session in small groups at a geriatric centre
Number of subjects: 804
Study 17701114 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional advice at the seniors home through one member of the interdisciplinary team
Number of subjects: 804
Study 17701114 — intervention group
Group type: COMPARATOR
Intervention: Refusal to participate in health promoting programmes
Number of subjects: 804
Study 16078132 — intervention group
Group type: EXPERIMENTAL
Intervention: Sum of inverse Gaussian functions for hydromorphone
Number of subjects: 0
Study 16078132 — intervention group
Group type: EXPERIMENTAL
Intervention: Sum of inverse Gaussian functions for veralipride
Number of subjects: 0
Study 16078132 — intervention group
Group type: COMPARATOR
Intervention: Sum of inverse Gaussian functions
Number of subjects: 0
Study 16078132 — intervention group
Group type: COMPARATOR
Intervention: Nonparametric method using linear splines
Number of subjects: 0
Study 11923036 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum concentrations of sICAM‐1 in cases (n = 136)
Number of subjects: 272
Study 11923036 — intervention group
Group type: COMPARATOR
Intervention: Baseline serum concentrations of sICAM‐1 in controls (n = 136)
Number of subjects: 272
Study 11923036 — intervention group
Group type: EXPERIMENTAL
Intervention: Each 100 ng/ml increase in sICAM‐1 concentration
Number of subjects: 272
Study 11923036 — intervention group
Group type: EXPERIMENTAL
Intervention: sICAM‐1 concentration in the highest quartile (>394 ng/ml)
Number of subjects: 272
Study 11923036 — intervention group
Group type: EXPERIMENTAL
Intervention: After adding fibrinogen to the multivariate model
Number of subjects: 272
Study 11923036 — intervention group
Group type: EXPERIMENTAL
Intervention: After adding total white blood cell count to the multivariate model
Number of subjects: 272
Study 9534836 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 77
Study 9534836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 8548947 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin
Number of subjects: 6
Study 8548947 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH
Number of subjects: 6
Study 8548947 — intervention group
Group type: COMPARATOR
Intervention: rhGH
Number of subjects: 6
Study 2082308 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 10 mg
Number of subjects: 18
Study 2082308 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 90 mg
Number of subjects: 18
Study 2082308 — intervention group
Group type: COMPARATOR
Intervention: Morphine sulfate 10 mg
Number of subjects: 18
Study 476704 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide plus prednisone (CP)
Number of subjects: 89
Study 476704 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus BCNU plus prednisone (CBP)
Number of subjects: 89
Study 476704 — intervention group
Group type: COMPARATOR
Intervention: Both CP and CBP
Number of subjects: 89
Study 31888371 — intervention group
Group type: EXPERIMENTAL
Intervention: Woodcast
Number of subjects: 120
Study 31888371 — intervention group
Group type: COMPARATOR
Intervention: Fibreglass cast
Number of subjects: 120
Study 31125325 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Strength Training (FST)
Number of subjects: 144
Study 31125325 — intervention group
Group type: COMPARATOR
Intervention: Traditional Strength Training (TST)
Number of subjects: 144
Study 28103714 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaze‐contingent music reward therapy
Number of subjects: 40
Study 28103714 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 40
Study 26529006 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula enriched with Metlin
Number of subjects: 0
Study 26529006 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula enriched with Metlos
Number of subjects: 0
Study 26529006 — intervention group
Group type: COMPARATOR
Intervention: Infant formula only (control)
Number of subjects: 0
Study 23490599 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 0
Study 23490599 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 0
Study 23490599 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 0
Study 20689328 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 72
Study 20689328 — intervention group
Group type: COMPARATOR
Intervention: Calcium acetate
Number of subjects: 72
Study 20689328 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol and calcium concentration in the dialysate adjusted according to serum calcium, phosphate and PTH
Number of subjects: 72
Study 19801040 — intervention group
Group type: EXPERIMENTAL
Intervention: PM101 (50 mg/ml, bolus push)
Number of subjects: 224
Study 19801040 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose in water)
Number of subjects: 224
Study 19801040 — intervention group
Group type: COMPARATOR
Intervention: Standard loading dose of AIV (150 mg, infused at 1.5 mg/ml over 10 minutes)
Number of subjects: 224
Study 19801040 — intervention group
Group type: COMPARATOR
Intervention: Rapid loading dose of AIV (150 mg, infused undiluted at 50 mg/ml over 15 seconds)
Number of subjects: 224
Study 16412749 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and low molecular weight heparin treatment in women with APS
Number of subjects: 10
Study 16412749 — intervention group
Group type: COMPARATOR
Intervention: Natural cycle donor insemination (Control)
Number of subjects: 10
Study 15644572 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 62
Study 15644572 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 62
Study 11317114 — intervention group
Group type: EXPERIMENTAL
Intervention: Active therapy
Number of subjects: 148
Study 9394635 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive frame
Number of subjects: 0
Study 9394635 — intervention group
Group type: COMPARATOR
Intervention: Negative frame
Number of subjects: 0
Study 8203857 — intervention group
Group type: EXPERIMENTAL
Intervention: Gram-positive prophylaxis with 10(6) U of penicillin i.v. every 6 hours (or 750 mg of vancomycin i.v. q12h if penicillin allergic) in addition to standard antimicrobial prophylaxis.
Number of subjects: 43
Study 8203857 — intervention group
Group type: COMPARATOR
Intervention: Standard antimicrobial prophylaxis (400 mg of norfloxacin orally three times a day, 200 mg of fluconazole orally once a day, and 5 mg of acyclovir per kg of body weight i.v. q12h) without gram-positive prophylaxis.
Number of subjects: 43
Study 3038722 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant interferon‐alpha 2A at 10 mU per m2
Number of subjects: 41
Study 3038722 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant interferon‐alpha 2A
Number of subjects: 41
Study 3038722 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 41
Study 29717197 — intervention group
Group type: EXPERIMENTAL
Intervention: NGM282 1 mg
Number of subjects: 0
Study 29717197 — intervention group
Group type: EXPERIMENTAL
Intervention: NGM282 6 mg
Number of subjects: 0
Study 29717197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29717197 — intervention group
Group type: EXPERIMENTAL
Intervention: NGM282 (1 mg and 6 mg)
Number of subjects: 0
Study 29717197 — intervention group
Group type: EXPERIMENTAL
Intervention: NGM282
Number of subjects: 0
Study 26962902 — intervention group
Group type: EXPERIMENTAL
Intervention: Labor induction between 39 weeks 0 days and 39 weeks 6 days of gestation
Number of subjects: 619
Study 26962902 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (waiting for spontaneous onset of labor or medical indication for induction)
Number of subjects: 619
Study 26962902 — intervention group
Group type: EXPERIMENTAL
Intervention: Labor induction
Number of subjects: 619
Study 26962902 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 619
Study 24039194 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 hours of intravenous prehydration before HDMTX infusion
Number of subjects: 47
Study 24039194 — intervention group
Group type: COMPARATOR
Intervention: 4 hours of intravenous prehydration before HDMTX infusion
Number of subjects: 47
Study 22743321 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg L and 1 mg Z supplementation
Number of subjects: 97
Study 20591841 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring of ICD leads
Number of subjects: 40
Study 20591841 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic interrogation every 3 months
Number of subjects: 40
Study 19078818 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous lidocaine (0.5 ml of 2% lidocaine 2 min before arterial puncture)
Number of subjects: 54
Study 19078818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl chloride (immediately before arterial puncture)
Number of subjects: 54
Study 19078818 — intervention group
Group type: COMPARATOR
Intervention: Nothing (routine skin preparation before arterial puncture)
Number of subjects: 54
Study 16008071 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME)
Number of subjects: 24
Study 16008071 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 12442604 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate solution (25 grams carbohydrates)
Number of subjects: 100
Study 12442604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 10517342 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified radical mastectomy or breast conservation treatment
Number of subjects: 227
Study 7739851 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 g caffeine administered orally
Number of subjects: 40
Study 7739851 — intervention group
Group type: COMPARATOR
Intervention: Control group (8 subjects)
Number of subjects: 40
Study 7739851 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine elimination measured at 12 hours post-administration
Number of subjects: 40
Study 2288833 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER 10 mg once daily
Number of subjects: 100
Study 2288833 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine R 20 mg twice daily
Number of subjects: 100
Study 340131 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (2 g once daily for 3 consecutive days)
Number of subjects: 60
Study 340131 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (2 g once daily for 3 consecutive days)
Number of subjects: 60
Study 30198451 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality plus morphine
Number of subjects: 80
Study 30198451 — intervention group
Group type: COMPARATOR
Intervention: Morphine alone
Number of subjects: 80
Study 29021268 — intervention group
Group type: EXPERIMENTAL
Intervention: PLUS (3 sessions/week for 12 weeks, then maintenance classes for 12 additional weeks)
Number of subjects: 29
Study 29021268 — intervention group
Group type: COMPARATOR
Intervention: LITE (2 sessions/week for 12 weeks)
Number of subjects: 29
Study 26116444 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional shared decision-making (IP-SDM) toolkit
Number of subjects: 0
Study 26116444 — intervention group
Group type: COMPARATOR
Intervention: Diabetes guidelines summary (Control)
Number of subjects: 0
Study 23628457 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 154
Study 23628457 — intervention group
Group type: COMPARATOR
Intervention: Endeavor zotarolimus-eluting stent (ZES)
Number of subjects: 154
Study 23628457 — intervention group
Group type: COMPARATOR
Intervention: Resolute zotarolimus-eluting stent (ZES)
Number of subjects: 154
Study 21802037 — intervention group
Group type: EXPERIMENTAL
Intervention: Contract-Relax group (CR)
Number of subjects: 60
Study 21802037 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Contract-Relax group (MCR)
Number of subjects: 60
Study 21802037 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 60
Study 19884591 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized 3% hypertonic saline with epinephrine
Number of subjects: 46
Study 19884591 — intervention group
Group type: COMPARATOR
Intervention: Nebulized 0.9% saline with epinephrine (Control)
Number of subjects: 46
Study 16702864 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrastromal corneal rings (360 degrees)
Number of subjects: 72
Study 14675406 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous methotrexate (HDMTX) (6-8 g/m2) with intrathecal methotrexate (ITMTX)
Number of subjects: 2090
Study 14675406 — intervention group
Group type: EXPERIMENTAL
Intervention: XRT and a short course of ITMTX
Number of subjects: 2090
Study 14675406 — intervention group
Group type: COMPARATOR
Intervention: ITMTX alone
Number of subjects: 2090
Study 14675406 — intervention group
Group type: COMPARATOR
Intervention: HDMTX plus ITMTX
Number of subjects: 2090
Study 11703217 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-based health education program (n=18), multidisciplinary approach, cognitive behavioral therapy exercises, 7 sessions over 5 months
Number of subjects: 38
Study 11703217 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 38
Study 9044225 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (CRE) - 20g.d‐1 for 3 d
Number of subjects: 9
Study 9044225 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) - drink only
Number of subjects: 9
Study 9044225 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) - no supplementation
Number of subjects: 9
Study 7941189 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic maintenance hemodialysis
Number of subjects: 20
Study 7941189 — intervention group
Group type: COMPARATOR
Intervention: Renal transplantation
Number of subjects: 20
Study 3282501 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% levobunolol hydrochloride
Number of subjects: 78
Study 3282501 — intervention group
Group type: COMPARATOR
Intervention: timolol maleate
Number of subjects: 78
Study 3282501 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobunolol hydrochloride
Number of subjects: 78
Study 3282501 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol maleate
Number of subjects: 78
Study 31638433 — intervention group
Group type: EXPERIMENTAL
Intervention: INS + ACA
Number of subjects: 124
Study 31638433 — intervention group
Group type: COMPARATOR
Intervention: INS + MET
Number of subjects: 124
Study 28691866 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax 600 mg multiple ascending dose
Number of subjects: 48
Study 28691866 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (various doses)
Number of subjects: 48
Study 28691866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 27486219 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT)
Number of subjects: 43
Study 27486219 — intervention group
Group type: COMPARATOR
Intervention: Conventional walking training (CWT)
Number of subjects: 43
Study 25937511 — intervention group
Group type: EXPERIMENTAL
Intervention: RHS-led gardening intervention (n = 373)
Number of subjects: 777
Study 25937511 — intervention group
Group type: COMPARATOR
Intervention: Teacher-led gardening intervention (n = 404)
Number of subjects: 777
Study 24000874 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ACE‐Is users
Number of subjects: 616
Study 24000874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent ACE‐Is users
Number of subjects: 616
Study 24000874 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous or intermittent users of other antihypertensive drugs
Number of subjects: 616
Study 24000874 — intervention group
Group type: EXPERIMENTAL
Intervention: Never‐users of antihypertensive drugs
Number of subjects: 616
Study 24000874 — intervention group
Group type: COMPARATOR
Intervention: ACE‐Is users (continuous or intermittent)
Number of subjects: 616
Study 20621401 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1g intravenously
Number of subjects: 30
Study 20621401 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium 75 mg intramuscularly
Number of subjects: 30
Study 18294084 — intervention group
Group type: EXPERIMENTAL
Intervention: MLR MPH (Biphentin), once per day
Number of subjects: 17
Study 18294084 — intervention group
Group type: EXPERIMENTAL
Intervention: IR MPH (Ritalin), twice per day
Number of subjects: 17
Study 18294084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 17081832 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa flavanol-enriched snack bar containing 1.5 g phytosterol
Number of subjects: 67
Study 17081832 — intervention group
Group type: COMPARATOR
Intervention: Control product containing no phytosterols
Number of subjects: 67
Study 14998365 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical estimation by ophthalmologists
Number of subjects: 7
Study 11293459 — intervention group
Group type: EXPERIMENTAL
Intervention: Thematic relations in concepts
Number of subjects: 0
Study 11293459 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaningful and salient thematic relations
Number of subjects: 0
Study 9146849 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (Gb)
Number of subjects: 8
Study 9146849 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-trans-hydroxy-glibenclamide (M1)
Number of subjects: 8
Study 9146849 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-cis-hydroxy-glibenclamide (M2)
Number of subjects: 8
Study 9146849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7712966 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic sclerotherapy
Number of subjects: 141
Study 7712966 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 141
Study 3282531 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg oral pimobendane (UD-CG 115)
Number of subjects: 8
Study 3282531 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral pimobendane (UD-CG 115)
Number of subjects: 8
Study 30336168 — intervention group
Group type: EXPERIMENTAL
Intervention: Film-forming chlorhexidine gluconate (CHG) preparation
Number of subjects: 0
Study 30336168 — intervention group
Group type: COMPARATOR
Intervention: Water-soluble chlorhexidine gluconate (CHG) preparation
Number of subjects: 0
Study 28349496 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-gingerol 10 mg orally twice daily for 12 weeks
Number of subjects: 88
Study 28349496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 25996351 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 0
Study 23406156 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinoplasty for non-deviated nose
Number of subjects: 191
Study 23406156 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinoplasty for deviated nose
Number of subjects: 191
Study 23406156 — intervention group
Group type: COMPARATOR
Intervention: Comparison of non-deviated vs deviated nose groups
Number of subjects: 191
Study 19942303 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotherapy (HT) + Endurance Training (ET)
Number of subjects: 21
Study 19942303 — intervention group
Group type: COMPARATOR
Intervention: Endurance Training (ET) only
Number of subjects: 21
Study 19629514 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheopheresis treatment (10 treatments within 17 weeks)
Number of subjects: 43
Study 19629514 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheopheresis treatment
Number of subjects: 43
Study 19629514 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 43
Study 17346595 — intervention group
Group type: EXPERIMENTAL
Intervention: In-vitro bond strength testing with mini-twin metallic premolar brackets bonded to 60 extracted premolars at 10 minutes, 24 hours, 1 week, and 4 weeks.
Number of subjects: 60
Study 17346595 — intervention group
Group type: EXPERIMENTAL
Intervention: In-vivo bond strength testing with mini-twin metallic premolar brackets bonded to 60 premolars in 22 volunteers at 10 minutes, 24 hours, 1 week, and 4 weeks.
Number of subjects: 60
Study 17346595 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival analysis for bond failure probability in both in-vitro and in-vivo environments.
Number of subjects: 60
Study 15519257 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD‐CLS mode pacing
Number of subjects: 50
Study 15519257 — intervention group
Group type: COMPARATOR
Intervention: DDI mode pacing (control group)
Number of subjects: 50
Study 12529072 — intervention group
Group type: EXPERIMENTAL
Intervention: AOD disorders
Number of subjects: 797
Study 12529072 — intervention group
Group type: COMPARATOR
Intervention: No AOD disorders
Number of subjects: 797
Study 9738637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study 9738637 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 391
Study 9738637 — intervention group
Group type: COMPARATOR
Intervention: CRP levels
Number of subjects: 391
Study 9738637 — intervention group
Group type: COMPARATOR
Intervention: SAA levels
Number of subjects: 391
Study 8054959 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate supplementation (200 micrograms Cr as picolinate)
Number of subjects: 38
Study 8054959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 8054959 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate supplementation
Number of subjects: 38
Study 2856543 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (400 mcg)
Number of subjects: 11
Study 2856543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 2856543 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide
Number of subjects: 11
Study 30312985 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (5000 IU/w for insufficiency, 10,000 IU/w for mild deficiency, 15,000 IU/w for severe deficiency) plus lifestyle guidance
Number of subjects: 100
Study 30312985 — intervention group
Group type: COMPARATOR
Intervention: Control group received health education and lifestyle guidance
Number of subjects: 100